Market Overview

QIAGEN's QuantiFERON-TB® Gold Plus Wins UN Migration Agency's Tender


International Organization for Migration selects most advanced test
for latent TB infection

QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced
that QuantiFERON-TB® Gold Plus (QFT-Plus), the gold standard
in accurate, cost-effective testing for latent tuberculosis (TB)
infection, has been adopted by the International Organization for
Migration (IOM) for use in screening migrants for the infection.

As the United Nations migration agency, IOM coordinates comprehensive
healthcare for about 20 million migrants, refugees and asylum-seekers
around the world. The IOM tender covers use of QFT-Plus in 16 countries
in Africa, Asia and the Middle East facing public health challenges from
TB as part of their 5-year Global Plan to End TB 2016-2020.

QIAGEN is collaborating with governments and international institutions,
non-governmental organizations and commercial partners in fighting the
global epidemic of tuberculosis. Experts around the world are
increasingly recognizing that accurate, laboratory-based screening for
latent TB infections – which can progress to active, contagious
tuberculosis – is essential to effective TB control. So far in 2018, the
World Health Organization (WHO) and U.S. Centers for Disease Control
(CDC) all have endorsed latent TB screening with interferon-gamma
release assays (IGRAs) such as QIAGEN's fourth-generation QFT-Plus and
third-generation QuantiFERON-TB® Gold (QFT). Furthermore, the
International Panel Physicians Association (IPPA) has endorsed QFT-Plus

Please find the full press release here


View Comments and Join the Discussion!